| Old Articles: <Older 4511-4520 Newer> |
|---|
 |
Wired
January 18, 2008
Erin Biba |
Why Things Suck: Hearing Aids If your hearing starts to fade, get ready for sticker shock and frustration. Hearing aids can cost more than $3,000 apiece, they don't do a good job of correcting the problem, and insurance companies rarely pay for them.   |
Insurance & Technology
January 7, 2008
Peggy Bresnick Kendler |
Real-Time Information Crucial To Informed Healthcare Decisions Facing increased pressure to control costs, the health insurance industry must empower consumers to make informed healthcare decisions by providing them with access to real-time information. |
BusinessWeek
January 17, 2008
John Carey |
In the Real World, a Slew of Side Effects from Statins In clinical trials of statins, side effects were relatively rare. But many doctors believe they are more common in the real world. |
The Motley Fool
January 17, 2008
Michael P. Cecil |
2 Sources of Trouble for Vytorin You know that a drug study has gone very, very bad when you can't find out its results without a congressional inquiry. |
The Motley Fool
January 17, 2008
Brian Lawler |
The Good Times Roll for Pharmasset Shares ride high after the company releases positive clinical trial data. |
The Motley Fool
January 17, 2008
Brian Orelli |
EPIX's Epic Oops The EPIX clinical trial data on their Alzheimer's medication wasn't as positive as it first appeared. |
IndustryWeek
February 1, 2008
Jill Jusko |
Polymers that Shift and Shape Georgia Tech researchers develop smart materials for biomedical applications. |
The Motley Fool
January 16, 2008
Brian Lawler |
Better Safe Than Sorry at Theravance Pharmaceutical company Theravance is raising cash in advance of an FDA hearing. Investors, take note. |
The Motley Fool
January 16, 2008
Brian Orelli |
Forest Labs Not Down -- Yet Double-digit revenue growth is the highlight of a good quarter for Forest Labs, but the company will need a lot more than one solid quarter to get its stock growing again. |
The Motley Fool
January 16, 2008
Brian Lawler |
Talking With a Development-Stage Pharma An interview with Dr. Leslie Browne, CEO of development-stage drugmaker Pharmacopeia. |
| <Older 4511-4520 Newer> Return to current articles. |
